Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Fallopian Tube Neoplasms 17Lung Neoplasms 16Esophageal Squamous Cell Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Neoplasms 13Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Carcinoma 6Colorectal Neoplasms 5Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4HER2-positive Breast Cancer 3Carcinoma, Squamous Cell 3

Interventions

eribulin 1disitamab vedotin 1RC48 antibody 1Paclitaxel 1Gemcitabine 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-low Breast Cancer × Paclitaxel × Clear all
NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡